[{"indications": "Indications\u00a0in combination with other drugs, tuberculosis resistant to first-line\r\ndrugs", "name": "CYCLOSERINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.9 Antituberculosis drugs", "CYCLOSERINE"], "cautions": "Cautions\u00a0monitor haematological, renal, and hepatic\r\nfunction; interactions: Appendix 1\r\n(cycloserine)", "side-effects": "Side-effects\u00a0mainly neurological, including headache, dizziness,\r\nvertigo, drowsiness, tremor, convulsions, confusion, psychosis, depression\r\n(discontinue or reduce dose if symptoms of CNS toxicity); rashes,\r\nallergic dermatitis (discontinue or reduce dose); megaloblastic anaemia;\r\nchanges in liver function tests; heart failure at high doses reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3903.htm", "doses": ["Initially 250\u00a0mg every 12 hours for 2 weeks increased\r\naccording to blood concentration and response to max. 500\u00a0mg every\r\n12 hours; child 2\u201318 years see BNF for Children", "Blood concentration monitoring required especially\r\nin renal impairment or if dose exceeds 500\u00a0mg daily or if signs of\r\ntoxicity; blood concentration should not exceed 30\u00a0mg/litre"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk\u2014crosses the placenta"}]